Charles River Laboratories Total Liabilities
Charles River Laboratories total liabilities. Based on the latest financial reports, Charles River Laboratories (CRL) has total liabilities worth $4.69 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Charles River Laboratories (CRL) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Charles River Laboratories (1998–2025)
Total liabilities of Charles River Laboratories from 1998 to 2025. This chart illustrates how Charles River Laboratories's total liabilities have evolved over time, based on quarterly financial data. Check CRL financial resilience to evaluate the company's liquid asset resilience ratio.
Charles River Laboratories Competitors by Total Liabilities
The table below lists competitors of Charles River Laboratories ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
QXO, Inc.
NASDAQ:QXO
|
USA | $6.82 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $122.20 Million |
|
Lululemon Athletica Inc
F:33L
|
Germany | €3.49 Billion |
|
Elia Group SA/NV
BR:ELI
|
Belgium | €22.95 Billion |
|
Guosen Securities Co Ltd
SHE:002736
|
China | CN¥452.99 Billion |
|
Sichuan Chuantou Energy Co Ltd
SHG:600674
|
China | CN¥22.59 Billion |
|
Taiwan Mobile Co Ltd
TW:3045
|
Taiwan | NT$145.33 Billion |
|
Iflytek Co Ltd
SHE:002230
|
China | CN¥25.76 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Charles River Laboratories's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Charles River Laboratories assets under control.
Liquidity & Leverage Metrics
Charles River Laboratories Total Liabilities Ratios Explained
Charles River Laboratories total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Charles River Laboratories's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Charles River Laboratories (1998–2025)
The table below shows the annual total liabilities of Charles River Laboratories from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.92 Billion | -2.39% |
| 2024-12-31 | $4.02 Billion | -11.37% |
| 2023-12-31 | $4.54 Billion | -0.94% |
| 2022-12-31 | $4.58 Billion | +3.32% |
| 2021-12-31 | $4.43 Billion | +32.42% |
| 2020-12-31 | $3.35 Billion | +10.60% |
| 2019-12-31 | $3.03 Billion | +20.21% |
| 2018-12-31 | $2.52 Billion | +34.93% |
| 2017-12-31 | $1.87 Billion | +0.42% |
| 2016-12-31 | $1.86 Billion | +42.60% |
| 2015-12-31 | $1.30 Billion | +10.34% |
| 2014-12-31 | $1.18 Billion | +20.50% |
| 2013-12-31 | $979.96 Million | -0.32% |
| 2012-12-31 | $983.14 Million | -4.47% |
| 2011-12-31 | $1.03 Billion | -1.48% |
| 2010-12-31 | $1.04 Billion | +25.82% |
| 2009-12-31 | $830.27 Million | -13.56% |
| 2008-12-31 | $960.47 Million | +2.01% |
| 2007-12-31 | $941.57 Million | -1.21% |
| 2006-12-31 | $953.11 Million | +35.87% |
| 2005-12-31 | $701.48 Million | -38.71% |
| 2004-12-31 | $1.14 Billion | +252.43% |
| 2003-12-31 | $324.75 Million | -0.20% |
| 2002-12-31 | $325.40 Million | +21.03% |
| 2001-12-31 | $268.86 Million | -4.10% |
| 2000-12-31 | $280.35 Million | -40.72% |
| 1999-12-31 | $472.89 Million | +619.90% |
| 1998-12-31 | $65.69 Million | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more